*Not actual patients. Individual results may vary.

IL-1—A mediator of the inflammatory and destructive nature of RA

Overproduction of IL-1 has been implicated in autoinflammatory and autoimmune diseases such as NOMID and RA

Learn more >

Kineret effectively reduces the signs and symptoms
of RA1

Dose-related improvement in clinical response as seen in a clinical study of adult RA patients (Kineret + MTX vs placebo + MTX)2

*MTX=methotrexate. 
P<0.05 vs placebo.
P<0.01 vs placebo.
§P<0.001 vs placebo.
||ACR20=American College of Rheumatology 20% improvement.

Kineret + MTX significantly reduced joint destruction at 12 months1

§Differences and 95% confidence interval (CI) for the differences in change scores between placebo + MTX and Kineret + MTX.
Based on Wilcoxon rank-sum test.

References

  1. Kineret [Prescribing Information]. Stockholm, Sweden: Biovitrum AB; 2013. 2. Amgen Inc. Kineret* (anakinra) FDA Briefing Information, August 16, 2001. Available at: http://www.fda.goc/ohrms/dockets/ac/01/briefing/3779b1.htm.

IL-1—A mediator of the inflammatory and destructive nature of RA

Overproduction of IL-1 has been implicated in autoinflammatory and autoimmune diseases such as NOMID and RA

Learn more >

Kineret has a well-documented safety profile in RA1

  • 12+ years of clinical experience1
  • Short half-life (4-6 hours) allowing for a short washout period if therapy needs to be interrupted in RA patients for various reasons2
  • Documented safety profile in a real-world RA patient population with a broad range of disease activity, a variety of comorbid conditions (asthma, diabetes, chronic obstructive pulmonary disease, coronary artery disease, congestive heart failure, pneumonia), and who were on a variety of background medications1

Safety profile evaluated across a real-world RA patient population1

  • Those with asthma, diabetes, chronic obstructive pulmonary disease, coronary artery disease, congestive heart failure, and/or pneumonia
  • Those using multiple combinations of concomitant therapies
  • Those typically seen in clinical practice

Values are the percentage. P values were calculated using Fisher's exact test.

  • In clinical trials, serious infections with Kineret were primarily bacterial; no TB or serious opportunistic infections were reported2
  • Kineret has been associated with an increased incidence of serious infections (2%) vs placebo (<1%)†2
  • In long-term follow-up for up to 3 years, the incidence of serious infections did not increase with extended exposure to Kineret1
  • Discontinue Kineret if serious infection develops and do not initiate therapy in patients with active infections
  • A higher rate of serious infection has been observed in patients treated with concurrent Kineret and etanercept therapy than in patients treated with etanercept alone. Use of Kineret in combination with TNF blocking agents is not recommended

These infections consisted primarily of bacterial events such as cellulitis, pneumonia, and bone and joint infections.

References

  1. Data on File, Sobi, Inc.
  2. Kineret [Prescribing Information]. Stockholm, Sweden: Biovitrum AB; 2013.

IL-1—A mediator of the inflammatory and destructive nature of RA

Overproduction of IL-1 has been implicated in autoinflammatory and autoimmune diseases such as NOMID and RA

Learn more >

Kineret safety profile1,2

All patients in these 2 studies taking Kineret received the 100-mg/day fixed dose. Patients in one study were on stable doses of MTX. Patients in the other study were on a variety of DMARD medications or were DMARD-free.1

Injection site reactions (ISRs) were the most common adverse reactions1

  • The majority of ISRs were reported as mild and typically lasted for 14 to 28 days1
  • Were characterized by erythema, ecchymosis, inflammation, and/or pain1
  • ISRs were typically reported in the first 4 weeks1
  • 5.6% of patients withdrew from Kineret studies due to ISRs2

It is important that you inform your patients when they are starting treatment about the possibility of ISRs and to discuss the strategies to minimize or manage injection pain and delayed reactions.1

Click the button below to download the Kineret Patient Brochure for detailed ISR management strategies.

References

  1. Kineret [Prescribing Information]. Stockholm, Sweden: Biovitrum AB; 2013.
  2. Kineret FDA briefing information, July 17, 2001. Amgen Inc. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b1.htm. Accessed January 25, 2011.

IL-1—A mediator of the inflammatory and destructive nature of RA

Overproduction of IL-1 has been implicated in autoinflammatory and autoimmune diseases such as NOMID and RA

Learn more >

Kineret® 100 mg/day by subcutaneous injection

Flexibility in prescribing Kineret

Dosing for RA patients

  • The recommended dose of Kineret for the treatment of patients with RA is 100 mg/day by subcutaneous injection
  • Doses should be administered at approximately the same time every day
  • 100 mg every other day should be considered for RA patients with severe renal insufficiency or end-stage renal disease

Administration

  • Kineret is provided in single-use prefilled glass syringes
  • Instructions on appropriate use should be given by the healthcare provider to the patient or caregiver, who should not be allowed to administer Kineret until they demonstrate a thorough understanding of procedures and an ability to inject the product
  • Patients should be informed of allergic and other adverse reactions and advised of appropriate actions, and that the needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex) and should not be handled by latex-sensitive persons
  • Inform patients that Kineret may lower the ability of their immune system to fight infections. Advise patients of the importance of contacting their doctor if they develop any symptoms of infection
  • Thoroughly instruct patients and their caregivers on the importance of proper disposal and caution against the reuse of needles, syringes, and drug products

Click the button below to download the Kineret Patient Brochure and share with your patients—for additional information about dosing, administration, and managing expectations.

RA=rheumatoid arthritis.
Defined as creatinine clearance <30 mL/min, as estimated from serum creatinine levels.

Reference

  1. Kineret [Prescribing Information]. Stockholm, Sweden: Biovitrum AB; 2013.

IL-1—A mediator of the inflammatory and destructive nature of RA

Overproduction of IL-1 has been implicated in autoinflammatory and autoimmune diseases such as NOMID and RA

Learn more >

INDICATIONS

Kineret® is an interleukin-1 receptor antagonist indicated for:

Rheumatoid Arthritis (RA)

Cryopyrin-Associated Periodic Syndromes (CAPS)

IMPORTANT SAFETY INFORMATION